Pharmacokinetics of iohexol, a new nonionic radiocontrast agent, in humans.
Sixteen healthy men received iohexol intravenously at a concentration of 346 mg of iodine/mL. Doses of 500, 750, 1000, and 1500 mg of iodine/kg of body weight were administered to four volunteers each. Neither clearance nor percent of dose excreted in the urine showed any significant correlation with size of the dose. The overall mean (+/- SD) renal and total body clearances were 120 +/- 18.6 and 131 +/- 18.6 mL/min, respectively. The overall mean apparent volume of distribution was 165 (+/- 30.7) mL/kg. Urine contained 92.3 +/- 4.4% of the dose. Most of the drug (89.9%) was excreted within the first 12 h. An open three-compartment body model gave the best fit to the experimental data. The mean apparent first-order terminal elimination (gamma-phase) half-life was 12.6 h.
D000293:Adolescent; D000328:Adult; D003287:Contrast Media / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D007463:Iodobenzoates / Q000378:metabolism*; D007472:Iohexol; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000378:metabolism*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol